CAR-T | Lessons Learned | What's Next - 2021 World Medical Innovation Forum
May 2–4, 2022

CAR-T | Lessons Learned | What’s Next

CAR-T | Lessons Learned | What’s Next

Wednesday, May 19, 2021

3:00 PM – 3:25 PM

Few areas of potential cancer therapy have had the attention and excitement of CAR-T. This panel of leading executives, developers, and clinician-scientists will explore the current state of CAR-T and its future prospects. Among the questions to be addressed are:

  • Is CAR-T still an industry priority – i.e. are new investments being made by large companies? Are new companies being financed? What are the trends?
  • What have we learned from first-generation products, what can we expect from CAR-T going forward in novel targets, combinations, armored CAR’s and allogeneic treatment adoption?
  • Early trials showed remarkable overall survival and progression-free survival. What has been observed regarding how enduring these responses are?
  • Most of the approvals to date have targeted CD19, and most recently BCMA. What are the most common forms of relapses that have been observed?
  • Is there a consensus about what comes after these CD19 and BCMA trials as to additional targets in liquid tumors? How have dual-targeted approaches fared?
Marcela Maus, MD, PhD
  • Director, Cellular Immunotherapy Program, Cancer Center, MGH
  • Associate Professor, Medicine, HMS
Jakob Dupont, MD
  • EVP, Head of Research and Development, Atara Biotherapeutics
Kristen Hege, MD
  • Senior Vice President, Early Clinical Development, Hematology/Oncology & Cell Therapy, BMS
Stefan Hendriks
  • Global Head, Cell & Gene, Novartis
Christi Shaw
  • CEO, Kite, a Gilead Company
  • Q&A

    03:30 PM – 03:45 PM

the Future of Medicine and AI

May 11–13, 2020 | Boston, MA